CRVS
Price
$4.12
Change
+$0.09 (+2.23%)
Updated
Jun 3 closing price
Capitalization
317.71M
69 days until earnings call
TNXP
Price
$39.86
Change
-$0.59 (-1.46%)
Updated
Jun 4, 01:59 PM (EDT)
Capitalization
296.28M
68 days until earnings call
Interact to see
Advertisement

CRVS vs TNXP

Header iconCRVS vs TNXP Comparison
Open Charts CRVS vs TNXPBanner chart's image
Corvus Pharmaceuticals
Price$4.12
Change+$0.09 (+2.23%)
Volume$739.04K
Capitalization317.71M
Tonix Pharmaceuticals Holding
Price$39.86
Change-$0.59 (-1.46%)
Volume$100
Capitalization296.28M
CRVS vs TNXP Comparison Chart
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TNXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. TNXP commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and TNXP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (CRVS: $4.12 vs. TNXP: $40.45)
Brand notoriety: CRVS and TNXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 65% vs. TNXP: 89%
Market capitalization -- CRVS: $317.71M vs. TNXP: $296.28M
CRVS [@Biotechnology] is valued at $317.71M. TNXP’s [@Biotechnology] market capitalization is $296.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileTNXP’s FA Score has 2 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • TNXP’s FA Score: 2 green, 3 red.
According to our system of comparison, TNXP is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 6 TA indicator(s) are bullish while TNXP’s TA Score has 3 bullish TA indicator(s).

  • CRVS’s TA Score: 6 bullish, 4 bearish.
  • TNXP’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CRVS is a better buy in the short-term than TNXP.

Price Growth

CRVS (@Biotechnology) experienced а +12.26% price change this week, while TNXP (@Biotechnology) price change was +9.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.19%. For the same industry, the average monthly price growth was +4.99%, and the average quarterly price growth was -2.11%.

Reported Earning Dates

CRVS is expected to report earnings on Aug 12, 2025.

TNXP is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+6.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRVS($318M) has a higher market cap than TNXP($296M). TNXP YTD gains are higher at: 22.650 vs. CRVS (-22.991). CRVS has higher annual earnings (EBITDA): -31.13M vs. TNXP (-76.74M). TNXP has more cash in the bank: 55M vs. CRVS (44.2M). CRVS has less debt than TNXP: CRVS (1.15M) vs TNXP (8.69M). TNXP has higher revenues than CRVS: TNXP (11.3M) vs CRVS (0).
CRVSTNXPCRVS / TNXP
Capitalization318M296M107%
EBITDA-31.13M-76.74M41%
Gain YTD-22.99122.650-102%
P/E RatioN/A0.11-
Revenue011.3M-
Total Cash44.2M55M80%
Total Debt1.15M8.69M13%
FUNDAMENTALS RATINGS
CRVS vs TNXP: Fundamental Ratings
CRVS
TNXP
OUTLOOK RATING
1..100
2411
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
87100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
4734
P/E GROWTH RATING
1..100
9812
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TNXP's Valuation (28) in the Pharmaceuticals Other industry is somewhat better than the same rating for CRVS (66) in the Pharmaceuticals Major industry. This means that TNXP’s stock grew somewhat faster than CRVS’s over the last 12 months.

CRVS's Profit vs Risk Rating (87) in the Pharmaceuticals Major industry is in the same range as TNXP (100) in the Pharmaceuticals Other industry. This means that CRVS’s stock grew similarly to TNXP’s over the last 12 months.

CRVS's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as TNXP (96) in the Pharmaceuticals Other industry. This means that CRVS’s stock grew similarly to TNXP’s over the last 12 months.

TNXP's Price Growth Rating (34) in the Pharmaceuticals Other industry is in the same range as CRVS (47) in the Pharmaceuticals Major industry. This means that TNXP’s stock grew similarly to CRVS’s over the last 12 months.

TNXP's P/E Growth Rating (12) in the Pharmaceuticals Other industry is significantly better than the same rating for CRVS (98) in the Pharmaceuticals Major industry. This means that TNXP’s stock grew significantly faster than CRVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSTNXP
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 6 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 14 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TNXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HLPPX9.870.02
+0.20%
LDR Real Estate Value Opportunity P
MMKBX22.54N/A
N/A
Morgan Stanley Inst Emerging Mkts A
PNOCX82.22N/A
N/A
Putnam Sustainable Leaders C
MSCRX10.37N/A
N/A
Madison Small Cap R6
FZABX29.50N/A
N/A
Fidelity Advisor Diversified Intl Z

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
+2.23%
SYRE - CRVS
37%
Loosely correlated
+7.60%
VKTX - CRVS
35%
Loosely correlated
+1.88%
IPSC - CRVS
34%
Loosely correlated
+4.89%
FULC - CRVS
34%
Loosely correlated
+1.08%
VCYT - CRVS
33%
Poorly correlated
-0.90%
More